Dr. Reddys Laboratories Ltd.

Dr. Reddy's Laboratories has launched Bortezomib for Injection 3.5 mg/vial, approved by the US Food and Drug Administration (USFDA) via a 505(b) (2) new drug application (NOA) pathway for intravenous use only.

The company’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.